THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES

Mason, Kayleigh

Abstract

Introduction: Whether psoriasis patients exposed to biologic
therapies have an elevated risk of keratinocyte carcinoma (KC),
including basal cell carcinoma (BCC) or cutaneous squamous cell
carcinoma (cSCC) remains uncertain. Objective:The aim of the present study was to determine whether such patients were at higher risk of developing a KC compared to those on conventional therapy.

Methods: The British Association of Dermatologists Biologic Interventions Register (BADBIR), a pharmacovigilance register of psoriasis patients, explores the long-term safety of systemic therapies. Patients with chronic plaque psoriasis registering to BADBIR on their first biologic or a conventional therapy, who had at least one follow-up completed were included in analyses if they were of white ethnicity, Fitzpatrick skin types 1–4 and reported no previous cancers. Confounding factors included: age; sex; smoking; and previous exposure to acitretin, psoralen ultravioletA (PUVA), ciclosporin, and/or PUVA and ciclosporin. Propensity score-weighted Cox-proportional hazard models estimated the hazard ratio (HR) for developing a first KC or separately, first BCC or cSCC.

Results: In total, 5672 patients initiating biologic therapy and 3188 patients on conventional therapy who met the entry criteria were identified with 20558 and 7829 person-years of follow-up, respectively. During follow-up, 74 (1.3%) patients initiating a biologic therapy were diagnosed with their first KC (43 BCC; 34 cSCC first) and 22 (0.7%) patients receiving conventional therapy with their first KC (15 BCC; 10 cSCC first). No significant difference in risk was observed for developing a KC (adjusted HR 1.05; 95% CI 0.64, 1.73), BCC (0.84; 95% CI 0.45, 1.54) or cSCC (1.20; 95% CI 0.57, 2.50) on biologic compared to conventional therapy.

Conclusion: Biologic therapy does not appear to confer a higher risk of developing a first KC as compared to conventional therapy in psoriasis patients. These data will help inform clinical decision making in psoriasis patients at risk of KC in whom biologic or conventional therapy is being considered. On behalf of the BADBIR Study Group, British Association of Dermatologists, London, UK

Citation

Mason, K. (2018, June). THE RISK OF KC IN PSORIASIS PATIENTS RECEIVING BIOLOGICS COMPARED TO CONVENTIONAL SYSTEMIC THERAPIES. Poster presented at 5th World Psoriasis & Psoriatic Arthritis Conference, Stockholm, Sweden

• Presentation Conference Type: Poster
• Conference Name: 5th World Psoriasis & Psoriatic Arthritis Conference
• Conference Location: Stockholm, Sweden
• Start Date: Jun 27, 2018
• End Date: Jun 30, 2018
• Deposit Date: Jun 28, 2023
• Publisher URL: https://www.medicaljournals.se/acta/content/abstract/10.2340/00015555-2978